Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Ardelyx to Contact Him Directly to Discuss Their Options

New York, New York--(Newsfile Corp. - November 6, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors of the November 16, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX).

[You may also click here for additional information]

WHY: Faruqi & Faruqi, LLP, a leading national securities law firm, informs investors of the federal securities class action on behalf of all investors who purchased or otherwise acquired Ardelyx common stock between January 13, 2025, and August 6, 2026, inclusive (the "Class Period").

If you wish to serve as lead plaintiff, you must move the Court no later than November 16, 2026. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

THE ALLEGATIONS:

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that the true state of Ardelyx's commercial performance and growth prospects for XPHOZAH and IBSRELA, and in particular the increasing payer-related access and reimbursement barriers affecting patient access, more stringent prior authorization requirements and step edit requirements that slowed new-patient starts and delayed prescription fulfillment.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Ardelyx's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Frequently Asked Questions (FAQ) for Investors Regarding the Ardelyx Securities Class Action Lawsuit

Who may be eligible to participate in the lawsuit?

Investors who purchased or acquired Ardelyx (NASDAQ: ARDX) between January 13, 2025 and August 6, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

How much did Ardelyx stock drop?

Following the alleged corrective disclosures, Ardelyx shares fell approximately 17% on August 7, 2026, as described in the complaint.

Why should investors contact Faruqi & Faruqi, LLP?

Faruqi & Faruqi, LLP is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Ardelyx securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/322742

Source: Faruqi & Faruqi LLP